Arcensus has Appointed Prof. Dr. Arndt Rolfs as New CEO

Published January 12th, 2022 - 07:54 GMT
Arcensus has Appointed Prof. Dr. Arndt Rolfs as New CEO
Dr. Arndt Rolfs
Highlights
Arcensus, a commercial-stage digital healthcare and diagnostics company that empowers people to take control of their health is pleased to announce that our Founder, Prof. Dr. Arndt Rolfs

Arcensus, a commercial-stage digital healthcare and diagnostics company that empowers people to take control of their health is pleased to announce that our Founder, Prof. Dr. Arndt Rolfs, a multi-entrepreneur in biotech and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE, has been appointed as the Chief Executive Officer of Arcensus GmbH.

Prof. Rolfs has succeeded the role from Mr. Michael Schlenk and assumed the responsibilities of CEO on January 01, 2022. We are very grateful for the hard work and dedication of Mr. Schlenk for successfully performing the duties of CEO in 2021 and constructing the organization of Arcensus. We are reassured that Mr. Schlenk will continue supporting Arcensus as an active member of our supervisory board.

Mr Schlenk wished the new CEO every success: "I wish Arndt and the operational team all the best for 2022. There is no doubt that this year will bring great progress for Arcensus after building the company so successfully in a record time. I look forward to supporting the shaping of the business model as a member of the Supervisory Board."

Prof Rolfs is an experienced biotech entrepreneur who knows the necessities and challenges of the healthcare industry very well. Under his leadership, Arcensus will disrupt the genetic diagnostics market through the rapid expansion of its global genomic service and develop new concepts based on genomic knowledge generated worldwide. Arcensus' genomic data already has a diagnostic yield of about 80% in all genetically suspect patients.

Prof Rolfs said: "Our expertise in the high-quality interpretation of Whole Genome DNA Sequencing data reflects the next revolution in modern medicine. Our global genomic knowledge will help pharma partners accelerate the development of new drugs, especially for rare diseases."

Background Information

Arcensus

Arcensus GmbH offers sophisticated genomics testing and preventive health services to give all individuals certainty and actionable insights about their health. The basis of the knowledge-generating direct-to-consumer business is an innovative WGS strategy. WGS captures all genetic variants that are missed in a single gene or panel testing. The direct-to-consumer business model allows the early identification of individuals suffering from a potential genetic disorder or those at risk for such problems. Such a strategy is particularly valuable when diseases are life-threatening or even fatal as sudden death or aortic dissection at their first presentation.

From our headquarters in Rostock and Berlin, Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone.

 For more information, visit 

Check out our PR service


Signal PressWire is the world’s largest independent Middle East PR distribution service.

Subscribe

Sign up to our newsletter for exclusive updates and enhanced content